ITK and lymphoma: Moreover, treatment of ITK–SYK+PD-1− lymphoma-bearing mice with the mTOR inhibitor torin-1, which blocks mTOR activity within tumor cells in vivo (Extended Data Fig. 3g), significantly prolonged survival (Fig. 2f and Extended Data Fig. 3h; P = 0.0057).